BioLine RX Ltd. Daily Stock Analysis

Daily Stock Analysis, BLRX, BioLine RX Ltd, priceseries

BioLine RX Ltd. Daily Stock Analysis
Stock Information
Open
1.50
Close
1.47
High
1.56
Low
1.47
Previous Close
1.55
Daily Price Gain
-0.08
YTD High
2.19
YTD High Date
Jan 18, 2022
YTD Low
1.34
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.61
YTD Gain
-29.33%
52 Week High
6.34
52 Week High Date
May 4, 2021
52 Week Low
1.34
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-1.26
52 Week Gain
-46.15%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 25. 2017
14.10
Feb 23. 2017
18.16
20 Trading Days
28.83%
Link
LONG
Jul 13. 2017
13.04
Jul 25. 2017
13.89
8 Trading Days
6.50%
Link
LONG
Jul 26. 2017
14.39
Aug 16. 2017
16.99
15 Trading Days
18.05%
Link
LONG
Oct 2. 2017
17.25
Oct 12. 2017
18.37
8 Trading Days
6.51%
Link
LONG
Nov 24. 2017
15.60
Dec 6. 2017
16.42
8 Trading Days
5.26%
Link
LONG
Sep 18. 2018
13.57
Oct 9. 2018
18.44
15 Trading Days
35.86%
Link
LONG
Jan 7. 2019
7.66
Jan 18. 2019
8.17
9 Trading Days
6.65%
Link
LONG
Apr 6. 2020
1.28
Apr 16. 2020
1.53
7 Trading Days
19.33%
Link
LONG
Jul 15. 2020
1.77
Aug 6. 2020
2.13
16 Trading Days
20.22%
Link
LONG
Nov 2. 2020
2.29
Nov 9. 2020
2.42
5 Trading Days
5.90%
Link
LONG
Dec 11. 2020
2.67
Dec 16. 2020
2.91
3 Trading Days
8.90%
Link
LONG
Jan 28. 2021
2.93
Jan 29. 2021
3.08
1 Trading Days
5.29%
Link
LONG
Feb 2. 2021
2.95
Feb 16. 2021
3.38
9 Trading Days
14.56%
Link
LONG
Apr 21. 2021
2.78
May 10. 2021
3.40
13 Trading Days
22.40%
Link
Company Information
Stock Symbol
BLRX
Exchange
NasdaqCM
Company URL
http://www.biolinerx.com
Company Phone
972-2-548-9100
CEO
Philip Adam Serlin
Headquarters
-
Business Address
2 HAMA-AYAN STREET, MODI-IN TECHNOLOGY PARK, MODI-IN, ISRAEL 7177871
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001498403
About

BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Description

BioLineRx Ltd., a clinical stage biopharmaceutical development company, is engaged in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company's development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a resorbable polymer solution being developed to reduce or prevent the ventricular remodeling; BL-8040, a peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a polymer for the treatment of celiac disease; BL-5010, which is being developed as a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the Hepatitis C virus and other viral indications. It also has three therapeutic candidates in the preclinical stages of development, such as BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies/asthma; and BL-9020 for the treatment of type 1 diabetes. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading